Edge Medicine

Gene therapist Matt During and his team of trans-pacific researchers have announced a “significant advance” in their search for a potentially revolutionary treatment for Parkinson’s disease. Published in the prestigious journal Science the findings derive from a technique of inserting a synthetic gene into the brain using an inactivated virus. In a world first, the United States Food and Drug Administration has approved a trial to test the therapy for safety on 12 people with severe Parkinson’s, after promising results in animal trials. Click here for the NZEDGE hot profile on During.


Tags: gene therapy  Matthew During  Medical Health  Parkinson's Disease  Science  United States Food and Drug Administration  

Emilia Wickstead Helping Airline Make an Impression

Emilia Wickstead Helping Airline Make an Impression

Around the globe, airlines and hotels are collaborating with top fashion houses to reshape brand narratives, like Air New Zealand and their partnership with London-based Emilia Wickstead. Condé Nast Traveler’s Caitlin…